ISSUES OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH THE EYES OF AN ANESTHESIOLOGIST. EXPERIENCE OF PERIOPERATIVE ANESTHESIOLOGICAL SUPPORT AND INTENSIVE THERAPY IN PARATHYROID SURGERY-Reference-Cited by-同舟云学术

ISSUES OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH THE EYES OF AN ANESTHESIOLOGIST. EXPERIENCE OF PERIOPERATIVE ANESTHESIOLOGICAL SUPPORT AND INTENSIVE THERAPY IN PARATHYROID SURGERY

Published:2021-06-25 Issue:16 Volume:2 Page:4-16
ISSN:2616-4868
Container-title:Клінічна та профілактична медицина
language:
Short-container-title:Clin. and prev. med.

Author:

Denysenko A.I.^ORCID,Cherniy V.I.^ORCID,Tkachenko R.P.^ORCID

Abstract

Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney disease (CKD) in the third and above stages with manifestations of chronic renal failure (CRF), especially in patients undergoing hemodialysis. Despite the temporary effects obtained from taking calcimimetics, there is no significant breakthrough in the treatment of SHPT, and most of the patients require parathyroid surgery (PTS). This review describes the main pathophysiological changes in SHPT, their correction, summarizes the indications for PTS, reflects preoperative preparation, anesthetic management, perioperative intensive care, and possible complications associated with SHPT and CRF. The experience of treating 214 patients with SHPT, 237 PTS (23 in connection with relapse of SHPT), algorithm of examination, preoperative preparation, anesthetic management and perioperative intensive care are presented. In the postoperative period, patients are at risk of severe hypocalcemia and hungry bone syndrome, which require careful monitoring and calcium replenishment.

Publisher

State Institution of Science Research and Practical Center

Reference49 articles.

1. Bureo, J. C, Arévalo, J. C., Antón, J., Adrados, G., Jiménez Morales, J. L., Robles, N. R. (2015). Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol. Nutr., 62, 300–305. https://doi.org/ 10.1016/j.endoen.2015.08.007.

2. Levin, A., Bakris, G. L, Molitch, M. et al. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int., 71, 31–38. https://doi.org/10.1038/sj.ki.5002009.

3. Ramos, A. M, Albalate, M., Vázquez, S., Caramelo, C., Egido, J., Ortiz, A. (2008). Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int. Suppl ,74, 111., S88–S93. https://doi.org/10.1038/ki.2008.543.

4. Cunningham, J., Locatelli, F., Rodriguez, M. (2011). Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol., 6, 913–921. https://doi.org/10.2215/CJN.06040710.

5. van der Plas, W. Y., Noltes, M. E., van Ginhoven, T. M., Kruijff, S. (2019). Secondary and tertiary hyperparathyroidism: a narrative review. Scand. J. Surg., 109, (4), 271-278. https://doi.org/10.1177/1457496919866015.